FangZH
2021-11-09
Buy before ship sail!
U.S. government to buy $1 billion more worth of Merck's COVID-19 pill<blockquote>美国政府将再购买价值 10 亿美元的默克 COVID-19 药丸</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":844755373,"tweetId":"844755373","gmtCreate":1636463823628,"gmtModify":1636464631339,"author":{"id":4092020406448250,"idStr":"4092020406448250","authorId":4092020406448250,"authorIdStr":"4092020406448250","name":"FangZH","avatar":"https://static.tigerbbs.com/c19e9582eca6ebcd821e572efe18170c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Buy before ship sail!</p></body></html>","htmlText":"<html><head></head><body><p>Buy before ship sail!</p></body></html>","text":"Buy before ship sail!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/844755373","repostId":1133150195,"repostType":2,"repost":{"id":"1133150195","kind":"news","pubTimestamp":1636463600,"share":"https://www.laohu8.com/m/news/1133150195?lang=zh_CN&edition=full","pubTime":"2021-11-09 21:13","market":"us","language":"en","title":"U.S. government to buy $1 billion more worth of Merck's COVID-19 pill<blockquote>美国政府将再购买价值 10 亿美元的默克 COVID-19 药丸</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1133150195","media":"Reuters","summary":"Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by","content":"<p>Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc(MRK.N)and partner Ridgeback Biotherapeutics, the companies said on Tuesday.</p><p><blockquote>路透11月9日 - 默克公司（MRK.N）及其合作伙伴Ridgeback Biotherapeutics周二表示，美国政府将再购买价值10亿美元的COVID-19药丸。</blockquote></p><p> The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.</p><p><blockquote>政府在6月份同意以12亿美元购买170万个疗程的molnupiravir，现在正在行使购买140万个疗程的选择权。</blockquote></p><p> That brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.</p><p><blockquote>这使得担保课程总数达到 310 万门，价值 22 亿美元。默克表示，作为合同的一部分，政府有权再购买 200 万门课程。</blockquote></p><p> The drug has been closely watched since data last month showed that when given early in the illness it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p><p><blockquote>自从上个月的数据显示，对于那些最有可能患严重新冠肺炎的人来说，如果在疾病早期服用这种药物，它可以将死亡或住院的几率减半以来，这种药物一直受到密切关注。</blockquote></p><p> \"Molnupiravir, if authorized, will be among the vaccines and medicines available to fight COVID-19 as part of our collective efforts to bring this pandemic to an end,\" said Frank Clyburn, president of Merck's human health business.</p><p><blockquote>默克人类健康业务总裁弗兰克·克莱伯恩 (Frank Clyburn) 表示：“如果获得授权，莫努匹拉韦将成为可用于对抗 COVID-19 的疫苗和药物之一，作为我们结束这一流行病的集体努力的一部分。”</blockquote></p><p> With limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.</p><p><blockquote>由于治疗 COVID-19 患者的选择有限，美国政府还获得了数百万剂辉瑞公司 (PFE.N) 的竞争对手抗病毒药物，上周研究表明，该药物可将面临严重疾病风险的成年人住院或死亡的几率降低 89%。</blockquote></p><p> Merck's application with the U.S. Food and Drug Administration will be taken up by a panel of independent experts on Nov. 30, following which the regulator is expected to make a decision.</p><p><blockquote>默克公司向美国的申请。美国食品和药物管理局将于 11 月 30 日接受一个独立专家小组的审议，之后监管机构预计将做出决定。</blockquote></p><p> Britain last week became the first country in the world to clear the use of molnupiravir.</p><p><blockquote>英国上周成为世界上第一个批准莫努匹拉韦使用的国家。</blockquote></p><p> Merck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.</p><p><blockquote>默克预计到今年年底将生产 1000 万个疗程的该疗法，其中至少 2000 万个疗程将于 2022 年生产。</blockquote></p><p> The drugmaker's shares rose nearly 1% to $83.41 in premarket trading.</p><p><blockquote>该制药商的股价在盘前交易中上涨近 1%，至 83.41 美元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. government to buy $1 billion more worth of Merck's COVID-19 pill<blockquote>美国政府将再购买价值 10 亿美元的默克 COVID-19 药丸</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. government to buy $1 billion more worth of Merck's COVID-19 pill<blockquote>美国政府将再购买价值 10 亿美元的默克 COVID-19 药丸</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Reuters</strong><span class=\"h-time small\">2021-11-09 21:13</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc(MRK.N)and partner Ridgeback Biotherapeutics, the companies said on Tuesday.</p><p><blockquote>路透11月9日 - 默克公司（MRK.N）及其合作伙伴Ridgeback Biotherapeutics周二表示，美国政府将再购买价值10亿美元的COVID-19药丸。</blockquote></p><p> The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.</p><p><blockquote>政府在6月份同意以12亿美元购买170万个疗程的molnupiravir，现在正在行使购买140万个疗程的选择权。</blockquote></p><p> That brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.</p><p><blockquote>这使得担保课程总数达到 310 万门，价值 22 亿美元。默克表示，作为合同的一部分，政府有权再购买 200 万门课程。</blockquote></p><p> The drug has been closely watched since data last month showed that when given early in the illness it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.</p><p><blockquote>自从上个月的数据显示，对于那些最有可能患严重新冠肺炎的人来说，如果在疾病早期服用这种药物，它可以将死亡或住院的几率减半以来，这种药物一直受到密切关注。</blockquote></p><p> \"Molnupiravir, if authorized, will be among the vaccines and medicines available to fight COVID-19 as part of our collective efforts to bring this pandemic to an end,\" said Frank Clyburn, president of Merck's human health business.</p><p><blockquote>默克人类健康业务总裁弗兰克·克莱伯恩 (Frank Clyburn) 表示：“如果获得授权，莫努匹拉韦将成为可用于对抗 COVID-19 的疫苗和药物之一，作为我们结束这一流行病的集体努力的一部分。”</blockquote></p><p> With limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.</p><p><blockquote>由于治疗 COVID-19 患者的选择有限，美国政府还获得了数百万剂辉瑞公司 (PFE.N) 的竞争对手抗病毒药物，上周研究表明，该药物可将面临严重疾病风险的成年人住院或死亡的几率降低 89%。</blockquote></p><p> Merck's application with the U.S. Food and Drug Administration will be taken up by a panel of independent experts on Nov. 30, following which the regulator is expected to make a decision.</p><p><blockquote>默克公司向美国的申请。美国食品和药物管理局将于 11 月 30 日接受一个独立专家小组的审议，之后监管机构预计将做出决定。</blockquote></p><p> Britain last week became the first country in the world to clear the use of molnupiravir.</p><p><blockquote>英国上周成为世界上第一个批准莫努匹拉韦使用的国家。</blockquote></p><p> Merck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.</p><p><blockquote>默克预计到今年年底将生产 1000 万个疗程的该疗法，其中至少 2000 万个疗程将于 2022 年生产。</blockquote></p><p> The drugmaker's shares rose nearly 1% to $83.41 in premarket trading.</p><p><blockquote>该制药商的股价在盘前交易中上涨近 1%，至 83.41 美元。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.reuters.com/world/us/us-government-buy-14-mln-more-courses-mercks-covid-19-pill-2021-11-09/\">Reuters</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.reuters.com/world/us/us-government-buy-14-mln-more-courses-mercks-covid-19-pill-2021-11-09/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133150195","content_text":"Nov 9 (Reuters) - The U.S. government will buy another $1 billion worth of the COVID-19 pill made by Merck & Co Inc(MRK.N)and partner Ridgeback Biotherapeutics, the companies said on Tuesday.\nThe government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.\nThat brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.\nThe drug has been closely watched since data last month showed that when given early in the illness it could halve the chances of dying or being hospitalized for those most at risk of developing severe COVID-19.\n\"Molnupiravir, if authorized, will be among the vaccines and medicines available to fight COVID-19 as part of our collective efforts to bring this pandemic to an end,\" said Frank Clyburn, president of Merck's human health business.\nWith limited options to treat people with COVID-19, the U.S government has also secured millions of doses of Pfizer Inc's(PFE.N)rival antiviral drug, which last week was shown to cut by 89% the chance of hospitalization or death for adults at risk of severe disease.\nMerck's application with the U.S. Food and Drug Administration will be taken up by a panel of independent experts on Nov. 30, following which the regulator is expected to make a decision.\nBritain last week became the first country in the world to clear the use of molnupiravir.\nMerck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.\nThe drugmaker's shares rose nearly 1% to $83.41 in premarket trading.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":2755,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":18,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/844755373"}
精彩评论